Production (Stage)
FibroBiologics, Inc.
FBLG
$0.8087
-$0.0638-7.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.75M | 2.36M | 2.14M | 2.25M | 2.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.53M | 3.71M | 3.35M | 3.22M | 3.45M |
| Operating Income | -4.53M | -3.71M | -3.35M | -3.22M | -3.45M |
| Income Before Tax | -4.97M | -3.10M | -500.00K | 898.00K | -8.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.97M | -3.10M | -500.00K | 898.00K | -8.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.97M | -3.10M | -500.00K | 898.00K | -8.46M |
| EBIT | -4.53M | -3.71M | -3.35M | -3.22M | -3.45M |
| EBITDA | -4.48M | -3.67M | -3.31M | -3.19M | -3.42M |
| EPS Basic | -0.14 | -0.09 | -0.01 | 0.03 | -0.27 |
| Normalized Basic EPS | -0.08 | -0.06 | -0.01 | 0.02 | -0.17 |
| EPS Diluted | -0.14 | -0.09 | -0.01 | 0.03 | -0.27 |
| Normalized Diluted EPS | -0.08 | -0.06 | -0.01 | 0.02 | -0.17 |
| Average Basic Shares Outstanding | 36.67M | 34.13M | 33.52M | 32.72M | 31.13M |
| Average Diluted Shares Outstanding | 36.67M | 34.13M | 33.52M | 32.72M | 31.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |